Vertex Pharmaceuticals, headquartered in Boston, specializes in developing small molecule drugs for serious diseases, with four approved cystic fibrosis treatments and therapies for sickle cell disease. The company employs 5,400 people and explores innovative treatments for various conditions, including type 1 diabetes.
VRTX has been in the news recently: The CNBC Investing Club reported that the S&P 500 has rebounded to around 5,694, with increased investor confidence due to trade talks. Alnylam Pharmaceuticals Inc recently reported a first-quarter adjusted EPS loss of just 1 cent, which was better than the expected loss of $(1.03).
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
